Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 7.14 Million USD | 109.92% |
| 2021 | -72.05 Million USD | -9.07% |
| 2020 | -66.06 Million USD | 7.24% |
| 2019 | -71.21 Million USD | -107.11% |
| 2018 | -34.38 Million USD | 48.58% |
| 2017 | -66.87 Million USD | -26.61% |
| 2016 | -52.82 Million USD | 33.21% |
| 2015 | -79.08 Million USD | -248.05% |
| 2014 | -22.72 Million USD | -117.32% |
| 2013 | -10.45 Million USD | -398.31% |
| 2012 | 3.5 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 54.83 Million USD | 0.75% |
| 2023 Q1 | 54.43 Million USD | 661.82% |
| 2022 Q4 | 7.14 Million USD | -84.47% |
| 2022 Q2 | 17.03 Million USD | 140.65% |
| 2022 Q3 | 46 Million USD | 170.14% |
| 2022 FY | 7.14 Million USD | 109.92% |
| 2022 Q1 | -41.89 Million USD | 41.85% |
| 2021 Q4 | -72.05 Million USD | -5.95% |
| 2021 Q1 | -69.16 Million USD | -4.7% |
| 2021 FY | -72.05 Million USD | -9.07% |
| 2021 Q3 | -68 Million USD | 9.1% |
| 2021 Q2 | -74.81 Million USD | -8.17% |
| 2020 Q3 | -50.7 Million USD | 25.27% |
| 2020 Q1 | -50.51 Million USD | 29.07% |
| 2020 Q2 | -67.84 Million USD | -34.31% |
| 2020 Q4 | -66.06 Million USD | -30.29% |
| 2020 FY | -66.06 Million USD | 7.24% |
| 2019 Q3 | -77.52 Million USD | -19.87% |
| 2019 FY | -71.21 Million USD | -107.11% |
| 2019 Q4 | -71.21 Million USD | 8.13% |
| 2019 Q2 | -64.67 Million USD | -7.54% |
| 2019 Q1 | -60.14 Million USD | -74.9% |
| 2018 Q2 | -53.52 Million USD | -11.99% |
| 2018 Q1 | -47.79 Million USD | 28.53% |
| 2018 FY | -34.38 Million USD | 48.58% |
| 2018 Q4 | -34.38 Million USD | 26.7% |
| 2018 Q3 | -46.91 Million USD | 12.36% |
| 2017 Q1 | -27.71 Million USD | 47.54% |
| 2017 Q2 | -55.38 Million USD | -99.87% |
| 2017 Q3 | -48.6 Million USD | 12.23% |
| 2017 Q4 | -66.87 Million USD | -37.58% |
| 2017 FY | -66.87 Million USD | -26.61% |
| 2016 Q2 | -75.56 Million USD | 3.48% |
| 2016 FY | -52.82 Million USD | 33.21% |
| 2016 Q3 | -59.31 Million USD | 21.51% |
| 2016 Q4 | -52.82 Million USD | 10.94% |
| 2016 Q1 | -78.28 Million USD | 1.01% |
| 2015 Q2 | -13.68 Million USD | 86.3% |
| 2015 Q4 | -79.08 Million USD | -9.87% |
| 2015 Q3 | -71.97 Million USD | -425.93% |
| 2015 Q1 | -99.92 Million USD | -186.57% |
| 2015 FY | -79.08 Million USD | -248.05% |
| 2014 Q4 | -34.86 Million USD | -53.46% |
| 2014 Q1 | -54.87 Million USD | -450.21% |
| 2014 FY | -22.72 Million USD | -117.32% |
| 2014 Q2 | -49.79 Million USD | 9.27% |
| 2014 Q3 | -22.72 Million USD | 54.37% |
| 2013 Q2 | -10.8 Million USD | 0.0% |
| 2013 Q3 | -10.45 Million USD | 3.2% |
| 2013 FY | -10.45 Million USD | -398.31% |
| 2013 Q4 | -9.97 Million USD | 4.6% |
| 2012 Q4 | 6.56 Million USD | 229.6% |
| 2012 FY | 3.5 Million USD | 0.0% |
| 2012 Q3 | -5.06 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -287.952% |
| BioQuest Corp. | 177.38 Thousand USD | -3927.939% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 248.421% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 212.349% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | 469.78 Thousand USD | -1420.902% |
| Instadose Pharma Corp. | - USD | -Infinity% |